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ABSTRACT
Introduction: Acute hyperglycemia (blood 
glucose [BG] ≥400 mg/dL) is common in 
primary care. An outpatient protocol was 
developed to streamline the treatment of acute 
hyperglycemia. The objective was to determine 
if an outpatient hyperglycemia protocol could 
achieve a BG level of <300 mg/dL within 
4 hours.  Methods: Adult diabetic patients 
with acute symptomatic hyperglycemia 
(>400 mg/dL) without acute illness were 
recruited. Enrolled patients were managed 
with a protocol that included administration 
of 0.15 units/kg rapid-acting insulin given 
subcutaneously, hydration, hourly fingerstick 
blood sugars (FSBS), laboratory assessment, 
tailored diabetes education, and follow-up 
within 72 hours. Independent variables for data 
analysis included age, baseline FSBS, sodium, 
potassium, chloride, blood urea nitrogen, serum 
creatinine, CO2, venous glucose, and etiology 
(medications, diet, personal stress). Results: For 
the 27 patients enrolled, the average initial 
FSBS level (n=23) was 484 mg/dL, the average 
final FSBS level (n=27) was 274 mg/dL, 
and average time to achieve BG levels of 
<300 mg/dL was 2.35 hours. The protocol was 
successful in 20 patients (74%). The causes 
for seven protocol failures were nonclinical 
in nature. The patients’ weight and total 
time to goal were significantly associated 
with odds of protocol success. Personal stress 
significantly correlated with protocol failure. 
The protocol success group had a higher 
sodium level than the failure group (P=0.01). 
Weight and baseline BG showed decreased 
odds of protocol success (P=0.05 and P=0.04, 
respectively). Conclusions: Results of this pilot 
study suggest acute hyperglycemia without 
other acute illness can be managed on an 
outpatient basis. Outpatient interventions 
to address acute hyperglycemia need 
further investigation. Managing acute 
hyperglycemia in the outpatient setting could 
potentially decrease hospital admissions for 
hyperglycemic hyperosmolar syndrome and 
mild diabetic ketoacidosis.68 Diabetes Ther (2011)  2(2):67-80.
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INTRODUCTION
Diabetic ketoacidosis (DKA) and hyperglycemic 
hyperosmolar syndrome (HHS) contribute 
significantly to the estimated US$174 billion 
annual cost of diabetes mellitus.1 Of the 
$116 billion in medical expenditures attributed 
to diabetes, approximately 50% ($58 billion) 
are inpatient costs.1 DKA and HHS are managed 
initially by hospital emergency departments 
(EDs), followed by inpatient medical care. A 
typical ED visit involves at least a 4-hour wait 
time, is inconvenient, and the average costs for a 
visit without admission are estimated at ≥$1000. 
Wait time in the ED has increased in the last 
decade due to an increasing number of patients 
using the ED at the same time that more EDs are 
closing their doors.2
Nationally recognized management protocols 
only exist for hospital settings. These protocols 
exist as initial treatment after the DKA or HHS 
diagnosis has been established.3 There is evidence 
to suggest type 1 diabetes patients with mild 
DKA can be managed with rapid-acting insulin 
analogs in an outpatient setting.4-7 It is currently 
unknown if symptomatic, mild hyperglycemia 
in type 2 diabetes patients can be managed 
adequately in an outpatient setting. Most diabetes 
education centers have policies and procedures 
to contact physicians when a patient presents 
with high blood glucose (BG) levels. However, no 
established outpatient hyperglycemia protocol 
exists. The literature does describe common 
causes of acute metabolic decompensation: 
acute illness (ie, infection, myocardial infection), 
noncompliance with treatment, and new-onset 
diabetes. Significant contributing factors within 
the noncompliance group are omission of insulin 
therapy and substance abuse (especially alcohol 
and cocaine). Even using the costs in 1998, 
national estimates for hospitalization for diabetic 
emergencies are high at $10,876, with an average 
length of stay of 6.6 days.8
Physicians and physician assistants (PAs) in 
our primary-care clinic voiced concerns that 
diabetic patients with BG levels of >400 mg/dL 
needed a more focused and consistent clinical 
assessment and management. Concerns were 
raised regarding whether all patients should 
be triaged as outpatients with insulin in the 
office, or whether all patients with BG levels of 
>400 mg/dL should be automatically referred 
to the ED. Concerns were also raised regarding 
whether all patients with positive urine ketones 
should be sent to the ED. To address these 
concerns, a multidisciplinary team of a medical 
doctor (MD), PA, and pharmacist developed a 
standardized assessment and outpatient protocol 
for symptomatic hyperglycemia. Based on 
preliminary data using the protocol informally, 
we hypothesized that this management 
approach was feasible. The purpose of this pilot 
study was to determine if the use of an outpatient 
hyperglycemia protocol could achieve a BG 
level of <300 mg/dL within 4 hours. This paper 
describes the clinical outcome of 27 patients 




The Family Medicine Center (FMC) has 
approximately 2000 patients with diabetes, 
and includes an American Diabetes Association 
(ADA)-recognized diabetes self-management 
education (DSME) service on-site. The site 
trains both family medicine and pharmacy 
residents. The FMC conducts approximately Diabetes Ther (2011)  2(2):67-80. 69
60,000 visits per year. The diabetes population is 
predominantly African-American females in their 
50s with type 2 diabetes. Patients generally belong 
to lower socioeconomic groups, and therefore 
noncompliance due to lack of resources is very 
common. A total of 70% of the FMC population 
is insured by either Medicare or Medicaid (many 
are dual eligibles), and approximately 30% have 
a coexisting psychiatric diagnosis. The study was 
designed within a primary-care setting equipped 
to educate, manage, and coordinate care for 
patients with diabetes.
Study Design
This study was an uncontrolled case series.
Study Population
University of Oklahoma Health Sciences Center 
Institutional Review Board (IRB) approval was 
granted prior to study initiation. Participants were 
selected from outpatients seen at the FMC, who, 
upon presentation, were found to have a finger-
stick blood sugar (FSBS) level of >400 mg/dL, 
with hyperglycemic symptoms (polyuria, 
polydipsia, polyphagia, drowsiness, fatigue, blurry 
vision). The participants were aged between 20 
and 80 years, with known diabetes. Exclusion 
criteria included patients with large blood ketones 
(as measured by >1.5 mmol/L of ketones by the 
blood glucose and ketone monitoring system 
[Precision Xtra® meter, Abbott Laboratories, 
Abbott Park, Illinois, USA], because the severity of 
dehydration would prevent outpatient treatment), 
patients with initial venous glucose >700 mg/dL 
(given maximal fall in BG at 75-100 mg/dL per 
hour, those >700 would automatically fail the 
protocol due to time), and patients who were 
acutely ill (ie, fever, infection, acute myocardial 
infarction) as assessed by the medical team (see 
Table 1 in Appendix 1).
Methods and Procedures
Clinical decision-making related to acute 
hyperglycemia was summarized with the creation 
of an assessment document (see Appendix 1). 
The assessment document was intended as a 
medical decision-making tool to determine 
appropriateness for outpatient treatment. 
Patients who gave consent were managed by 
the use of a protocol for hyperglycemia using 
FSBS, rapid-acting insulin analog, hydration 
(either intravenous [IV] or oral), diabetes 
self-management education, and discharge 
instructions (see Appendix 2). The goal was to 
decrease BG levels by 75-100 mg/dL per hour.
The initial insulin dose was 0.15 units/kg 
subcutaneously (SQ) into the abdomen. This is 
the IV dose recommended by the ADA for HHS 
management.3 Subcutaneous administration 
was chosen so that the protocol would be 
simple, and because IV access in the outpatient 
environment is often unavailable. Subsequent 
insulin doses were determined by the physician 
and pharmacist. Any subsequent dose was very 
patient specific, and based on several factors: 
1) the rate of decline of the BG level after the 
first insulin dose; 2) amount of hydration given; 
3) the type of diabetes; 4) body weight; 5) body 
habitus; and 6) total daily insulin dose for 
current insulin users. Type 2 diabetes patients 
may have required additional insulin doses 
depending on the level of insulin resistance. 
Type 1 diabetes patients (a small percent of our 
diabetic population) are very insulin sensitive, 
and therefore required small amounts of insulin. 
Protocol patients received either a telephone 
follow-up or an appointment with the primary-
care physician or pharmacist-diabetes educator 
within 72 hours.
The protocol was carried out by a team of 
physicians, nurses or medical assistants (MA), and 
pharmacists. The physician’s role was to provide 70 Diabetes Ther (2011)  2(2):67-80.
patient-assessment, consult with the pharmacist 
to initiate the protocol, determine subsequent 
insulin dose(s), provide clinical decision-making 
when ED referral was warranted, and sign the 
progress note as required for billing purposes. 
The MA/licensed practical nurse’s (LPN) role was 
to start and administer IV fluids if necessary or 
ensure the patient was drinking water throughout 
the protocol, perform hourly FSBS, administer 
insulin SQ into the abdomen, coordinate the 
patient getting samples for statistical laboratory 
tests (stat labs) drawn, ongoing communication 
with the pharmacist for insulin dose-orders, 
documentation of every step in the protocol 
(FSBS results, amount of hydration given, stat lab 
results, insulin administration), and to ensure 
follow-up visits were scheduled. The pharmacist’s 
role was to interview patients, identify 
contributing factors to acute hyperglycemia, 
obtain consent, oversee nurses, ensure the 
protocol ran efficiently, provide basic self-
management education tailored to the patient’s 
needs during the protocol, and coordinate care if 
the patient had insufficient resources to maintain 
a supply of medication and/or related supplies 
(meter, test strips, lancets, syringes).
Data Collection, Analysis, and 
Confidentiality
Participants were assigned a unique identifier 
to ensure no patient could be identified by 
reviewing the clinical data. Demographics 
and clinical data were recorded onto the data-
collection form (see Appendix 3).
For all participants, the following data were 
collected: unique identifier, date of protocol, 
insurance, FSBS1, FSBS2, FSBS3, FSBS4, FSBS5 
(as applicable), time of FSBS1 through time of 
FSBS5, weight, amount of insulin administered, 
time insulin was administered, time venous 
blood was obtained, basic metabolic panel (BMP) 
results for sodium, potassium, chloride, CO2, BG, 
creatinine, blood urea nitrogen (BUN), urinalysis 
(UA) results, blood ketone results, second insulin 
dose (if given) and time of second insulin dose 
(if given), and factors contributing to high BG 
(medications, diet, recent illness, and/or personal 
stress). Personal stress included lack of housing or 
transportation, lack of personal support, recent 
emotional stress (death in the family, undergoing 
divorce), and financial stressors. Multiple factors 
could be indicated.
The primary objective of this study was to 
determine what proportion of patients could 
successfully achieve a BG level of <300 mg/dL 
within 4 hours. The secondary objective was an 
exploratory analysis of patient factors related to 
the primary objective (which factors may make 
the protocol more or less appropriate?).
Patients that failed to achieve a BG level of 
<300 mg/dL were assessed as protocol failures. To 
assess the potential association between protocol 
failure and baseline BG, an independent-
measure t-test was conducted, using baseline BG 
level as the dependent measure, and protocol 
success or failure as the independent measure. 
Additional Fisher’s exact tests were conducted to 
assess the potential association between reasons 
for failure and protocol failure. Additionally, 
various basal metabolic electrolyte levels were 
compared, based on protocol success or failure 
as the independent measure, and the various 
electrolyte measures as the dependent measure.
An exploratory analysis using logistic 
regression was conducted in an effort to assess 
the association between protocol outcome 
(success/failure as the dependent variable) 
and several independent variables, including 
ethnicity, baseline blood sugar, patient weight, 
and total time to goal. This analysis may assist 
in establishing what, if any, various independent 
variables were significantly associated with 
protocol success or protocol failure.Diabetes Ther (2011)  2(2):67-80. 71
For all analyses, the a-priori alpha level was 
0.05. All data management and analyses were 
performed in Stata (Version 10, StataCorp LP., 
Texas, USA).9
RESULTS
The baseline patient demographics are shown in 
Table 1. Results are summarized in Table 2. Of 
note, average initial FSBS level was 484 mg/dL, 
and over half (56%) had state Medicaid 
insurance. Average final FSBS level (n=27) was 
274 mg/dL. Three readings displayed on the 
screen as “HI,” signified that the BG level was 
>600 mg/dL on the Aviva glucometer (Accu-
Chek® Aviva; Roche Ltd., Indianapolis, Indiana, 
USA). Average time to achieve FSBS levels of 
<300 mg/dL was 2.35 hours, and 20 out of 
27 patients (74%) achieved an FSBS level of 
<300 mg/dL within 4 hours. Seven protocol 
failures were secondary to nonclinical issues, 
such as patient contact barriers (after hours, 
transportation, telephone). We excluded one 
patient with large blood ketones who was 
referred to the ED, because outpatient treatment 
was inappropriate. Patients that failed to achieve 
a BG level of <300 mg/dL were assessed as 
protocol failures. Table 3 depicts the exploratory 
analysis using logistic regression to assess the 
potential association between protocol outcomes 
(success/failure as the dependent variable) and 
several independent variables, including baseline 
BG level, race, weight, and total time to goal. As 
can be seen, the variables of patient weight and 
Table 1. Demographics.






Average age (years) 47
Payor mix, n=27 n (%)
Medicaid 15 (56)
Medicare 6 (22)
Commercial insurance 5 (19)
Self-pay 1 (4)
Table 2. Results of the use of a hyperglycemia protocol.
Initial FSBS >600 mg/dL
Average initial FSBS (n=23)




Average final FSBS (n=27)
Average time to achieve BG <300 mg/dL 
274 mg/dL
2.35 hours
Average fall in glucose between FSBS1 and 
FSBS2 
144 mg/dL
Average time between FSBS1 and FSBS2  1.45 hours
Patients that did not decrease by  
75 mg/dL in the first hour
4*
Protocol success  20/27 (74%)
Protocol failure 7/27 (26%)
Follow-up within 72 hours  27/27 (100%)
*Three of the four received a second insulin dose.
BG=blood glucose; FSBS=fingerstick blood sugar.
Table 3. Fisher’s exact test. Assessing the relationships 
between various causes of hyperglycemia (medications, 











Yes 5 15 0.85
Diet
No 5 2
Yes 12 8 0.59
Illness
No 5 2
Yes 17 3 0.43
Personal stress
No 3 4
Yes 17 3 0.0572 Diabetes Ther (2011)  2(2):67-80.
total time to goal were significantly associated 
with the odds of successful outcome. There was 
also a significant association between personal 
stress and protocol failure. Table 4 depicts the 
outcome of the Fisher’s exact tests, assessing the 
relationships between the various reasons for 
hyperglycemia (medications, diet, and personal 
stress) and protocol failure. Weight and baseline 
BG levels became significantly associated with 
decreased odds of protocol success (P=0.05 
and P=0.04, respectively). Table 5 depicts the 
results of the independent-measures t-tests of 
electrolytes from a BMP when the participants 
were grouped by success or failure. Note that 
there was a significant difference between 
the two groups regarding sodium levels, with 
the protocol success group having a higher, 
and statistically significant, mean sodium 
level than the failure group (P=0.01). There 
was no difference between the two groups of 
participants (success or failure) with regard 
to initial FSBS (mean failure 535.29 mg/dL 
[standard deviation (SD) 73.97], mean success 
489.2 mg/dL [SD 58.46], P=0.17). All patients 
>65 years of age failed (n=2). There was no 
statistically significant difference between the 
two groups of participants with regard to initial 
venous glucose (mean venous glucose in the 
failure group was 406 mg/dL [SD 55.28], and 
mean venous glucose in the success group was 
351 mg/dL [SD 62.08], P=0.072).
DISCUSSION
These preliminary data were generated in a 
“real-world” primary-care setting. It is hoped 
that these results can serve as preliminary 
data to demonstrate the effectiveness of this 
Table 4. Logistic regression.  Relationship of patient characteristics to protocol failure.
Variable Odds ratio Standard error z P>(z) 95% CI
African-American Referent Referent Referent Referent Referent
White 0.1749816 0.2225771 –1.37 0.171 0.0144631, 2.117011
Baseline BG 0.9770231 0.0108552 –2.09 0.036 0.9559773, 0.9985322
Weight 0.9824874 0.0089038 –1.95 0.050 0.9651904, 0.9896569
Total time to goal 0.1908757 0.1610927 –1.96 0.050 0.0365061, 0.9980126
Logistic regression: number of observations=27; P=0.00308; log likelihood=–11.007311; pseudo R2=0.2876.
BG=blood glucose; CI=confidence interval.
Table 5. Independent-measure t-tests.
Variable Observation (n) Mean (SD) 95% CI P value
Sodium
Failure 6 135.55 (1.95) 133.50, 37.60
Success 15 138.27 (1.97) 137.18, 39.36 0.010
Potassium
Failure 6 4.3 (0.22) 3.74, 4.86
Success 15 4.20 (0.16) 3.82, 4.51 0.63
Chloride
Failure 6 95.17 (3.97) 91.00, 99.33
Success 15 98.07 (2.96) 96.43, 99.71 0.15
CI=confidence interval; SD=standard deviation.Diabetes Ther (2011)  2(2):67-80. 73
protocol in a larger study. As the incidence of 
diabetes continues to increase, primary care 
will continually be challenged to find effective 
diabetes-management strategies, particularly 
strategies to lower costs. It was hypothesized 
that the protocol would be successful within 
4 hours for two reasons. Firstly, 4 hours is 
the average duration of rapid-acting insulin 
analogs, and secondly, utilizing one exam room 
for more than 4 hours would significantly alter 
patient flow. Our average time to goal was 
2.35 hours, significantly less than hypothesized. 
Most of the statistically significant results can 
be explained clinically. Firstly, personal stress 
correlated with protocol failure because cortisol, 
which is increased during stress responses, 
opposes insulin action, and worsens insulin 
resistance. Secondly, protocol success was more 
likely with higher-corrected sodium values. 
Serum sodium increases with dehydration, and 
most hyperglycemic patients are dehydrated 
from polyuria.
The average venous glucose was lower than 
the average initial FSBS for two reasons. Firstly, 
stat labs were difficult to obtain in a timely 
manner, and patient interviews were conducted 
in-between initial FSBS and venous blood drawn. 
Secondly, some patients received the first dose of 
insulin prior to the venous blood draw. The 4-hour 
“stopwatch” began at the time the initial FSBS 
was taken. Rather than wait ≥1 hour(s) to receive 
venous glucose results, the first dose of insulin 
was based on the initial FSBS value. By itself, 
baseline BG was not associated with protocol 
success or failure. Using multivariate logistic 
regression, we found baseline BG did become 
associated with protocol failure. Multivariate 
analysis also showed increasing weight correlated 
with decreased odds of protocol success by 3%. 
Obesity contributes to insulin resistance and the 
higher the initial BG, the more difficult it is to 
achieve a reduction in a timely manner.
Lessons Learned
In improving our diabetes population at large, 
a culture shift has been observed in both 
patients and providers. FSBS >400 mg/dL in 
an outpatient physician visit represents poorly 
controlled diabetes. Although fear of insulin 
exists in any diabetes population, the concept 
that insulin is required to reduce BG out of 
the “dangerous” range has at least been taken 
into consideration by patients and providers. 
Due to the fact that this protocol focuses on 
hydration, patients understand drinking water 
will help reduce high BG levels, in the clinic or 
at home. An effective outpatient hyperglycemia 
protocol must address hydration and insulin, 
because both are required for BG to decrease 
in a timely manner. Based on provider 
feedback, deciding who must be referred to 
the ED is clearer. The main limitation in this 
study is small sample size. Our results may 
not be generalizable to small practice settings 
and to practices without any formal diabetes 
education services. Fortunately, 100% of 
participants were available for follow-up within 
72 hours; none had been to the ED and no 
patients were hospitalized. Despite the benefit 
of having an ADA-recognized diabetes program 
on-site, not all study participants could be seen 
for continued diabetes education, because the 
payer for the majority of study patients did not 
include adult diabetes education as a covered 
benefit (see Table 1).
Practical Aspects
In order to appropriately triage patients with 
acute hyperglycemia, a team approach is 
required. As study patients could potentially 
need 4 hours in the clinic, keeping them 
in the same exam room was not feasible. 
After venous labs were drawn, patients were 74 Diabetes Ther (2011)  2(2):67-80.
managed either in the diabetes education 
service or in the same-day appointment 
clinic. Responsibility for the final FSBS must 
be assigned to a healthcare professional 
before patient discharge. The use of a blood 
ketone meter is convenient and reimbursable. 
Blood ketones should be assessed as soon 
as possible after a FSBS level of >400 mg/dL 
is identified, so that patients inappropriate 
for the outpatient protocol (ie, patients with 
large blood ketones) can be referred to the ED 
immediately. With increasing primary-care 
practices having access to diabetes educators 
and/or clinical pharmacists, the need for a 
simple, consistent approach to hyperglycemia 
management is needed. Diabetes self-
management training (DSMT) programs with 
the ability to receive reimbursement can bill 
for the diabetes education provided in this type 
of service (using G-codes G0108)10 on the same 
day as a physician office visit (evaluation and 
management codes). We were also successful 
in using outpatient critical-care codes, which 
receive higher reimbursement than established 
office visits (CPT code 99291, a billing code 
used to reflect higher acuity outpatient visits or 
patient encounters).
CONCLUSION
The use of an outpatient hyperglycemia 
protocol was successful in achieving a FSBS 
level of <300 mg/dL within 4 hours in 20 
out of 27 (74%) nonacutely ill primary-
care patients. Outpatient interventions to 
address acute hyperglycemia need further 
investigation. Although this study evaluated 
an acute issue, primary-care clinics need 
improved chronic-care models, because 
keeping patients with diabetes in a system of 
care allows for resolution of issues leading up 
to acute hyperglycemic episodes. Managing 
acute hyperglycemia in the outpatient setting 
could potentially decrease the frequency of 
hyperglycemia and diabetes emergencies, and 
DKA- and HHS-related hospital admissions.
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Primary care assessment1-5
Problem Patient with symptomatic hyperglycemia
Assessment Assess:
•	 Hemodynamic status: volume status/degree of dehydration
•	 Vomiting and ability to take p.o.
•	 Medication compliance
•	 Identify precipitating event leading to high glucose, (eg, infection, MI, omission of insulin,  
  CNS event, pancreatitis)
•	 Examine for occult infection (eg, skin, feet, UTI, cellulitis, sacral decubitus)
•	 Symptoms of hyperglycemia
•	 Diabetes-related complications
•	 Social and medical history (eg, EtOH)
•	 Rule out pregnancy if clinically relevant
•	 Presence of ketonemia and acid-base disturbance
Labs and tests  •	 FSBS per clinic glucometer
•	 Stat labs:
•	 glucose (lab), CBC, and BMP for Na, K, Cl, CO2, BUN, SCr
•	 UA, check urine ketones; if positive or if unable to void, check serum ketones
•	 Calculate or measure serum osmolarity, anion gap based on plasma glucose and clinical finding  
  (see below)
•	 If considering osmotically active substance other than glucose, measure osmolar gap
•	 Consider blood and/or urine cultures
•	 Consider chest x-ray
•	 Pregnancy test if clinically relevant
•	 Consider EKG
Diagnosis based on 
clinical findings and 
lab results
•	 Determination of diagnosis
•	 hyperglycemic (DX code 790.6)
•	 HHS (DX code 250.2)
•	 ketosis without acidosis
•	 DKA (DX 250.1)
•	 other acid-base disturbance (ie, lactic acidosis, alcoholic acidosis) 
BMP=basic metabolic panel; BUN=blood urea nitrogen; CBC=complete blood count; CNS=central nervous system; 
DKA=diabetic ketoacidosis; DX=diagnosis code; EKG=electrocardiogram; HHS=hyperglycemic hyperosmolar syndrome; 
MI=myocardial infarction; p.o.=oral; SCr=serum creatinine; UA=urinalysis; UTI=urinary tract infection.
APPENDIX 1
This protocol is designed to assist primary-care 
providers in creating an individualized plan 
of care for adult patients who present with 
hyperglycemia or diabetic ketoacidosis (DKA). 
This protocol is not intended to replace sound 
medical judgment or clinical decision-making. 
Clinical judgment determines the need for 
adaptation in all patient-care situations; more 
stringent or less stringent interventions may 
be necessary.Diabetes Ther (2011)  2(2):67-80. 77
Calculations
Calculation of effective serum osmolarity  2[Na+ + K+] + (glucose in mg/dL) + BUN 
                    18   2.8
Correction of serum sodium     [Na+] + 1.6 x [glucose in mg/dL] – 100 
                      100
Calculation of the anion gap     [Na+] – [Cl + HCO3] 
BUN=blood urea nitrogen.
Table 1. American Diabetes Association clinical practice guidelines (annual January supplement). Diagnostic criteria for 
DKA and HHS.6
DKA
Mild Moderate Severe HHS
Plasma glucose (mg/dL) >250 >250 >250 >600
Arterial pH 7.25-7.30 7.00-7.24 <7.00 >7.30
Serum bicarbonate (mEq/L) 15-18 10 to <15 <10 >15
Urine ketones* Positive Positive Positive Small
Serum ketones* Positive Positive Positive Small
Effective serum osmolality (mOsm/kg)† Variable Variable Variable >320
Anion gap‡ >10 >12 >12 Variable
Alteration in sensoria or mental obtundation Alert Alert/drowsy Stupor/coma Stupor/coma
Reproduced from: Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN.  Hyperglycemic Crises in Adult Patients with Diabetes.  
Diabetes Care. 2009;32(7):1335-1343. © 2009 by the American Diabetes Association.
*Nitroprusside reaction method.
†Calculation: 2[measured Na (mEq/L)] + glucose (mg/dL)/18.
‡Calculation: (Na+) – (Cl– + HCO3
–) (mEq/L). See text for details.
DKA=diabetic ketoacidosis; HHS= hyperglycemic hyperosmolar syndrome.
Admission strategy
Consider hospital ED referral if:
•	 hemodynamically unstable
•	 unable to take or maintain p.o. intake
•	 newly diagnosed type-1
•	 other apparent medical/surgical reasons
•	 severely dehydrated patient presents to clinic after 3:00 PM
Guideline authors: Becky Armor, Pharm.D., CDE, Frank Lawler, MD, Allene Jackson, MD, Kalyanakrishnan 
Ramakrishnan, MD.
ED=emergency department; p.o.=oral.78 Diabetes Ther (2011)  2(2):67-80.
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APPENDIX 2




Providers notified of protocol initiation:    	 Attending physician:
  	 Becky Armor, Pharm.D., CDE
Outpatient treatment 
For Blood Glucose (BG) above 400 mg/dL in a known diabetic patient:
   Order stat labs: BMP, CBC, Urinalysis and urine culture if clinically indicated.
   Give 0.15 units/kg of rapid acting insulin (Novolog, NovoNordisk, Princeton, New Jersey, USA) SQ into abdomen.
   Check blood ketones. Meter available in Silver clinic (Precision Xtra, Abbott Laboratories. Abbott Park, Illinois, U.S.A.).
   Check for STAT lab results. Establish oral or IV hydration.
   Recheck FSBS in 1 hour.
   Hydrate with 1 L (1000 mL) orally or IV. Consider IV hydration with 1 L NS over 1 hour if clinically indicated to   
  maintain hemodynamic stability.If IV hydration is needed, patient may be managed in the Green clinic with assigned   
  nurse or MA.
   At first hour: Page PharmD provider with BG result. If BG is below 300, discharge. If BG is above 300, page PharmD   
  provider for second insulin dose to administer. Follow up on stat lab results. Continue maximal hydration.
   Recheck FSBS in 1 hour.
   At second hour: If BG is below 300, discharge. If BG is above 300, page PharmD provider for the next insulin dose   
  to administer.
   Recheck FSBS in 1 hour.
   At third hour: If BG is below 300, discharge. If BG is above 300, page PharmD provider for the next insulin dose   
  to administer.
   Recheck FSBS in 1 hour.
   Re-establish diabetes drug therapy.
   Review patient instructions below, especially the need to force calorie free liquids and eat on schedule.
   Consider pharmacotherapy referral for intensification of diabetes treatment and basic self-management education.
   Provide patient with written instructions for follow-up care (yellow copy).
   Schedule return appointment or phone follow-up within 72 hours.
BG=blood glucose; BMP=basic metabolic panel; CBC=complete blood count; FSBS=fingerstick blood sugar; 
IV=intravenous; MA=medical assistance; NS=normal saline; STAT=lab order results are needed as soon as possible; 
SQ=subcutaneous.
Patient Instructions:
1.  Force calorie free fluids today (water, Crystal Light, diet Sprite, diet 7-Up).
2.  Resume your diabetic diet.
3.  Resume your usual diabetes medicines.
4.  Check your blood sugar every 3-4 hours today. If your bedtime blood sugar is GREATER THAN 300, call the   
  after-hours physician on call at 271-4311.





ID number  Weight (#)                     (kg)
Clinic  Temp:







Insulin 2  
dose  
time
Insulin 3  
dose  
time




FSBS 1 time: FSBS 2 time: FSBS 3 time: FSBS 4 time:
FSBS 1 result: FSBS 2 result: FSBS 3 result: FSBS 4 result:
Hydration:
IV hydration (in mLs)
p.o. hydration (in ounces)
Initial Labs:
Time BMP collected:
Time stat results available:
















  Infection   MI, stroke   Personal stress   Illicit drugs
BMP=basic metabolic panel; BUN=blood urea nitrogen; Cl=chloride; FSBS=fingerstick blood sugar; IV=intravenous; 
LPN=licensed practical nurse; MD=medical doctor; MI=myocardial infarction; Pharm D=doctor of pharmacy; 
SCr=serum creatinine; UA=urinalysis.